Blocking Galectin-9 led to marked tumor regression and synergized with anti-PD-1 therapy, suggesting that targeting Dectin-1 or its ligand may enhance immunotherapy efficacy in PDA.96 Here, LGALS9 is linked to Patent ductus arteriosus.